 Osmotica Pharmaceuticals plc OSMT through its subsidiary Osmotica Pharmaceutical US LLC Osmotica or the Company, a fully integrated biopharmaceutical company, announced today that the Company has resubmitted its New Drug Application NDA for arbaclofen extended release ER tablets for the alleviation of spasticity in Multiple Sclerosis MS patients to the U.S. Food and Drug Administration FDA. With the recent completion of our 12-month open-label study assessing the long-term safety and tolerability of arbaclofen ER 80 mgday - this resubmission also includes the full results of our second Phase 3 efficacy study OS440-3004. The safety and efficacy results from these studies, together with the entire data package from our clinical development program, supports the clinical significance of arbaclofen ER as a potential treatment for MS spasticity. 